Upper Tract Urothelial Cancer Treatment Granted Priority Review – Renal and Urology News
In a phase 3 trial, mitomycin gel for instillation showed a complete response rate of 59% of patients with low-grade upper tract urothelial cancer.
Related Articles
Voquezna Approved to Relieve Heartburn With Nonerosive GERD
The FDA has approved Voquezna (vonoprazan) for heartburn associated with nonerosive gastroesophageal reflux disease.
Aging Into Medicare Tied to Higher Drug Costs for People With Diabetes
Out-of-pocket costs for type 2 diabetes drugs increase as patients age into Medicare.
Large Geographic Variation Seen With Heart Failure Phenotypes
Global regional differences seen in patient characteristics, treatment, and outcomes
CDC Warns of Shortage of Bottles Needed for Crucial Blood Tests
(HealthDay News) — Hospitals and clinical laboratories across the United States are facing a critical shortage of bottles used to culture blood samples, federal health…
Be Wary of Patients’ Requests for Wellness Infusions
Physicians need to consider a number of factors when deciding whether to agree to patients’ requests for wellness infusions.
Immune-Related AEs Reported in 23% of Placebo Recipients in ICI Trials
Reports of irAEs are fairly common among patients receiving a placebo in trials of ICIs, according to researchers.
Preeclampsia in CKD Increases Risk for Kidney Function Decline, ESKD
Preeclampsia in women with chronic kidney disease increases their long-term risk for kidney function decline and end-stage kidney disease.
Five Members of Australia Women’s Polo Team Test Positive for COVID-19 Ahead of Paris 2024 Olympics
COVID-19 makes an unwanted appearance ahead of the Paris 2024 Olympics. Five Australia polo players are following protocols and wearing masks.
Rate of MASLD Increasing Among Patients With Type 2 Diabetes Worldwide
The rate of MASLD and MASH continues to increase globally among individuals with type 2 diabetes, many of whom also have advanced fibrosis.
Out-of-Pocket Costs May Hinder Diagnostic Testing for Prostate Cancer
Researchers found that out-of-pocket costs for prostate biopsy and MRI increased “substantially” from 2010 to 2020.